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Abstract 
In drug discovery, the potential of cytochrome 
P450 inhibition of new chemical entities (NCEs) 
is frequently quantified in terms of IC50 values. 
In early drug discovery a risk-classification into 
low, medium or high potential inhibitors is often 
sufficient for ranking and prioritizing of 
compounds. While often six or more inhibitor 
concentrations are used to determine the IC50 
value, the question arises whether it is possible to 
predict the risk-class based on fewer inhibitor 
concentrations with comparable reliability. In the 
present article we propose a new integrated two-
point method with inhibitor concentrations chosen 
in accordance with the risk-classification. We 
analyse its predictive power and the feasibility to 
not only classify the compounds into different risk 
classes but also rank those compounds that have 
been binned into the middle risk class. The 
proposed integrated two point method is thus 
highly suitable for automation. Altogether it 
maintains the quality of the prediction while 
considerably reducing time and cost. The 
proposed method is applicable to other IC50 
assays and risk classifications.  
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1  Introduction 
Cytochrome P450 (CYP) mediated metabolism accounts for the main 
pathway of drug elimination from the body for the 200 world best 
selling drugs [10]. Inhibition of these metabolic enzymes by a 
coadministered second drug can lead to a substantial increase of the 
parent drug concentration [6]. This effect is commonly known as ’CYP 
mediated drug-drug interaction’, and may give rise to severe side 
effects up to the necessity of a drug withdrawal from the market [9]. 
Therefore, along with determination of target potency and selectivity of 
a new chemical entity (NCE), it is common practise in drug discovery 
to screen for the CYP inhibitory potential applying various types of 
assays [11]. In early project phases, it may be sufficient to qualitatively 
guide the progress of the project by the so-called Crespi assay [2], a 
flow chart of which is depicted in Fig. 1. In a broad sense, the obtained 
IC50 values are used for ranking purposes within one compound series 
and binned into classes exhibiting a high (IC50<1 µM), a moderate 
(1 µM<IC50<10 µM) and a low (IC50>10 µM) potential for drug-drug 
interaction (DDI). In later project phases, more time and cost intensive 
assays are used to characterise the compounds of interest more 
accurately [1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Principle of the Crespi assay: Fluorogenic substrates are 
metabolised by a recombinant human CYP iso-enzyme to its 
fluorescent metabolite. An IC50 value can be calculated from the 
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reduced fluorescence upon addition of increasing concentrations of a 
test compound. The IC50 is categorized into classes with a high (IC50 
below 1 µM ), medium (IC50 between 1 µM and 10 µM ), and low 
(IC50 above 10 µM ) risk potential. 
To keep pace with the dynamics of drug discovery and further 
economize these routinely used in vitro assays, mathematical methods 
were exploited in order to predict IC50 values with as few as possible 
inhibitor concentrations while maintaining a high correlation to the 
reference IC50 assay with six inhibitor concentrations. As has been 
reported in [7, 8], the predictive power of methods based on one or two 
inhibitor concentrations varies with the chosen concentrations and 
suffers from increasing variability at IC50 values far away from the 
chosen inhibitor concentrations. To fix this drawback, either the 
statistical model is changed, as in [7], or different (a priori unknown) 
inhibitor concentrations are chosen for different compounds, as in [8]. 
Neither solution seems satisfactory from a theoretical nor a practical 
point of view. The present study focuses on the problem of how to 
reliably predict the risk-classes, in some sense a coarse-grained IC50 
value, with as few as possible inhibitor concentrations and how to 
optimally choose the concentrations to obtain most reliable predictions. 
Applying the herein proposed approach, we obtain a high predictive 
quality (90% correctly predicted). Furthermore, the variability at the 
most critical regions is minimized by choosing inhibitor concentrations 
at the boundary of the risk-classes (1 µM and 10 µM for the chosen risk 
classification depicted in Fig. 1) and thereby avoiding the above 
mentioned drawbacks. The presented approach can easily be adapted to 
various assay types and different risk classifications. 
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2  Materials and Methods 
2.1 Materials 
For our analysis 290 compounds resulting from different drug-
discovery projects have been arbitrarily chosen from the Schering 
compound library. Inhibitory controls (1A2: Furafyllin, 2C9: 
Sulfaphenazole, 2C19: Tranylcypromine, 2D6: Quinidine, 3A4: 
Ketokonazole) were purchased from Sigma Aldrich (St. Louis, MO). 
Other reagents were taken from the commercially available CYP High 
Throughput Inhibitor Screening Kits ® (Kat. Nos. 459100 (1A2), -200 
(2C9), 300 (2C19), -400 (2D6) and -500 (3A4)) from BD-Gentest 
(Woburn, MA). 96-well plates were taken from Greiner Bio-One 
(Frickenhausen, Germany) using the black Greiner FIA plate model 
(Kat. No. 655076). Human recombinant cytochrome P450 enzymes 
were used as received in concentrations as listed in Table I. 
Fluorogenic substrates of the various iso enzymes were 3-Cyano-7-
ethoxycoumarin (CEC) for CYP1A2 and 2C19, 7-Methoxy-4-
trifluoromethylcoumarin (7-MFC) for CYP2C9, 3-[2-(NN-Diethyl-N-
methylamino)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for 
CYP2D6 and 7-Benzyloxy-trifluoromethylcoumarin (7-BFC) for 
CYP3A4. Potassium phosphate buffer at pH 7.4 was used as incubation 
media, cofactors consisted of Glucose-6-phosphate (G6P), NADP+, 
MgCl2, and G6P-dehydrogenase (G6PD) and acetonitrile / Tris Base at 
0.5 M (80/20, (v/v)) served as stop reagent. 
 
2.2 CYP Inhibition Crespi Assay 
The assay was carried out according to the protocol published by 
Crespi and Stresser [1]. Incubations were performed by using a 
Heidolph Titramax 1000 incubator (Heidolph Instruments, Schwabach, 
Germany) at 37°C and 750 rpm for 15 min-45 min (see Table I). A 
Fluostar® Galaxy plate reader (BMG-Labtechnologies, Offenburg, 
Germany) was used for fluorometric data generation. Concentrations of 
the various components are listed in Tab 1. Test compounds were 
dissolved in acetonitrile to a stock solution at 3 mM yielding in a final 
solvent concentration of 2% in the assay. The compounds were 
investigated with regard to their DDI potential for the CYP iso-
enzymes 1A2, 2C9, 2C19, 2D6, 3A4. IC50 determinations were based 
on six concentrations at 0.12, 0.37, 1.1, 3.3, 10, and 30 µM, and were 
performed at least in duplicates. Only compounds with an IC50 less 
than 30 µM were taken as a basis for the study since this group of 
compounds is the more critical and challenging one. For compounds 
showing inconsistent data, the IC50 has been corrected by excluding 
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misleading data points from the calculation. Compounds exhibiting 
auto-fluorescence were excluded from the data evaluation because for 
these compounds an IC50 determination cannot be reliably performed 
using the Crespi Assay.  
 
2.3  Dose-Response Models 
The commonly used model to determine the IC50 of a NCE from given 
in vitro data is to fit the sigmoid dose-response  
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derived from the Hill equation [4, 5, 8] to the experimental data, where 
x denotes the inhibitor concentration, max the maximal percent 
inhibition, and min the minimal percent inhibition of the enzyme. 
Often, min and max are set to 0% respectively 100%, and we adopt this 
practise here. Moreover, h denotes the Hill coefficient that determines 
the slope of the sigmoidal curve and reflects the extent of cooperativity 
[7]. The IC50 value and the Hill coefficient are determined by solving a 
non-linear least-squares problem [3] in order to minimize the 
differences between the model and the experimental inhibition data.  
 
Different number of experimental data (inhibitor concentrations) can be 
used as a basis for fitting the sigmoid dose-response model. In broad 
terms, the more data are used for the fit, the more accurately the IC50 
can be determined, since outliers and variability in the experimental 
conditions will be averaged out. However, particularly in the early 
stages of drug discovery, a rough determination of the CYP inhibition 
potential of a NCE without many (costly) measurements is desired for 
ranking and prioritization purposes within one programme.  
 
For our study, the reference scheme for determining the risk-class is 
based on the six-point IC50, i.e., fit of the sigmoid dose-response 
model to the six data points ranging from 0.12 µM to 30 µM. This 
method is taken as a reference to evaluate the predictive power of the 
integrated two-point method, i.e., fit of the sigmoid dose-response 
model 
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to two data points at 1.1 µM  and 10 µM (chosen in accordance with 
the risk classification), with variable Hill coefficient or with h=1. In 
[4], Gao et al. suggested the use of a one-point method. In this case, 
the IC50 can be determined explicitly by solving for IC50:  
 
xatinhibitionpercent
xatinhibitionpercent
xIC −×= 10050  (3) 
under the additional assumption that the Hill coefficient is fixed to one. 
In our analysis, the one-point method at 1.1 µM, 3.3 µM or 10 µM is 
included.  
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3  Results 
In the following subsections, the different methods will be studied 
w.r.t. their ability to classify a compound into the same risk-class as the 
reference six-point IC50 method. This is done by plotting the predicted 
IC50 of the one-/two-point method versus the six-point IC50. 
3.1  One-Point method at 1.1 µM, 3.3 µM, or 
10 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Comparison of the IC50 values on five major CYP Isoforms 
for 290 compounds obtained by the one-point method at 1.1 µM (left) 
and 10 µM (right) vs. the six-point IC50 values. Compounds for which 
the predicted risk-class differs from the six-point risk-class are marked 
with a black circle. 
The one-point method at 1.1 µM, 3.3 µM or 10 µM allows obtaining 
good predictions for compounds with an IC50 close to the 
corresponding inhibitor concentration at 1.1 µM, 3.3 µM, or 10 µM, 
respectively (see Fig. 2 and Fig. 3, left). However, the larger the 
difference between the six-point IC50 and the chosen inhibitor 
concentration for the one point method, the larger are the variations of 
the predicted IC50 values. In other words, the one-point method at 
1.1 µM focuses on the range of IC50 values around 1.1 µM, while the 
one-point method at 10 µM focuses on the range of IC50 values around 
10 µM (and analogous for 3.3 µM). In addition, due to the usage of just 
a single measurement, even negative IC50 values are predicted from 
eq. (3): there are eight negative IC50 values predicted by the one-point 
method at 1.1 µM, six negative predictions by the one-point method at 
10 µM, and zero negative predictions by one-point method at 3.3 µM 
(points not shown in Fig. 2 and 3).  
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Figure 3:  Comparison of the IC50 values for 290 compounds on five 
major CYP Isoforms obtained by the one-point method at 3.3 µM (left) 
and the weighted one-point method at 1.1 and 10 µM (right) vs. the six-
point IC50 values. Compounds for which the predicted risk-class 
differs from the six-point risk-class are marked with a black circle. 
 
One possibility of fixing the disadvantage of either one-point 
methods is to combine two IC50 values in a weighted sum. Denote by 
IC50
x
 the IC50 value at x=1.1 µM or x=10 µM. Then we define the 
weighted sum by  
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with wx = |(percent inhibition at x µM) − 50)|. The above weighting scheme 
between the two IC50 values is designed in such a way that the 
inhibitor concentration with percent inhibition closer to 50% inhibition 
has more control of the overall IC50 value. As a result, the predictive 
power increases (see Fig. 3, right). However, still there is the 
possibility of predicting negative IC50 values (two negative 
predictions). 
Another strategy to fix the disadvantage of the one-point methods 
could be to choose out of two IC50 values the one whose IC50 value is 
closest to its underlying inhibitor concentration. The results are 
comparable to the method based on the above weighting scheme (data 
not shown). 
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3.2 Integrated two-point method at 1.1 µM and 
10 µM 
 
 
 
 
 
 
 
Figure 4:  Comparison of the IC50 values for 290 compounds on five 
major CYP Isoforms obtained by the integrated two-point method with 
fixed Hill coefficient (h=1, right) and with variable Hill coefficient 
(left) vs. the six-points IC50 values. Compounds for which the 
predicted risk-class differs from the six-point risk-class are marked 
with a black circle. 
 
Instead of combining two one-point IC50 values, the integrated two-
point method directly fits the sigmoid dose-response model to two data 
points. The IC50 values resulting from the integrated two-point method 
are shown in Fig. 4 for variable Hill coefficient (left) and fixed Hill 
coefficient, h=1, (right), as in the case of the one-point methods. While 
the one-point methods at most allow to classify the compounds into the 
three different risk classes, the integrated two-point methods not only 
has a higher reliability to classify into the three risk classes, it also 
offers the possibility to rank compounds in the middle risk class. In 
order to quantify the correlation  between the IC50 value of the six-
point and the integrated two point method, Pearson correlation 
coefficients were computed based on all 290 compounds and based 
solely on those compounds that have been ranked into the middle risk-
class (by the integrated two point method). As can be inferred from 
Table II, the overall correlation is less than 89% (for both methods), 
while the correlation in the middle risk class is as high as 95%.  
3.3  Comparison of the different methods 
In Table II the overall performance of the different methods is 
compared. For each method, the percentage of correctly predicted risk-
classes, the number of data points in each risk-class, and the Pearson 
correlation coefficients based on all 290 compounds and based only the 
those compounds that have been ranked into the middle risk class are 
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reported. As a result, the integrated two-point method turns out to be 
the most reliable method. 
 
 
 
 
4  Discussion 
 
Streamlining in vitro assays to make them more cost-effective is of 
high importance when dealing with an increasing number of 
compounds in times of growing time, capacity und budget restrains. 
However, streamlining is only cost-effective, if it does not come at the 
cost of losing predictive power or accuracy, i.e. maintains the value of 
the assay for decision-making. We have therefore analysed 
mathematically how the six point CYP inhibition IC50 assay can be 
slimmed down without compromising its predictive power and hence 
its use for drug discovery. 
Our analysis of the one-point method [4] at 1.1 µM, 3.3 µM and 10 µM 
clearly reveals some serious limitations. The one-point method has its 
predictive focus for IC50 values close to the inhibitor concentration 
used (1.1 µM, 3.3 µM or 10 µM, respectively). The larger the 
difference of the used inhibitor concentration to the predicted IC50 
value, the larger the dispersion (see Fig. 2 and Fig. 3, left). In [4], Gao 
et al. analyzed the potential of using a single inhibitor concentration to 
estimate IC50 values. While their model well predicted the (logarithm 
of the) IC50 value for a small test set of compounds based on a single 
inhibitor concentration at 3 µM, they had to modify and increase the 
complexity of the model to regain a comparable predictive quality 
when analyzing additional 396 new compounds: ’With the larger set, it 
was found necessary to either fit a curve or fit a model with several 
slopes’, [4]. From our analysis, this effect can easily be explained: The 
larger and more diverse the set of compounds the more diverse the 
range of IC50 values. As a consequence, the variability at values 
distant from the chosen inhibitor concentration increases and thereby 
decreasing the quality of the one-point method. In addition, the 
theoretical justification of their analysis is arguable since—based on 
the relation in eq. (1)—one would not expect a linear relation between 
the percent inhibition at x and the log(IC50) value, as done in [4]. 
Rather, one would expect a hyperbolic relation, which can nicely be 
seen in Fig. 4 of Gao et al. [4].  
 
The insight in the one-point methods motivated the use of two-point 
methods. In [5], Moody et al. also analyzed the predictive power of a 
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two-point IC50 method. They found a high correlation between IC50 
values computed by a seven-point method versus their two-point 
method. However, they used different inhibitor concentrations for their 
two-point method depending on the IC50 value predicted by the seven 
point method: 0.5 and 5 µM were used for inhibitors with IC50 lower 
than 0.5 µM; while 5 and 50 µM were used for inhibitors with IC50 
between 0.5 and 250 µM; and 50 and 500 µM were used for inhibitors 
with IC50 greater 250 µM [5]. This way, they obtain a good correlation 
between their two-point IC50 and the seven-point IC50. However, by 
this method, a pre-IC50 determination needs to be done thereby not 
significantly lowering the time and costs to be invested. 
 
Trying to overcome this practical limitation we advised a new 
integrated two-point method based on inhibitor concentrations chosen 
at the boundaries of the risk-classes, in our case 1.1 and 10 µM. This 
way, we force the method to be as accurate as possible around the set 
risk boundaries. This results in a highly reliable classification into the 
three categories. The performance can be seen in Fig. 4: While the 
dispersion is moderate at 1.1 and 10 µM, it increases at either end, 
where, however, it does not have any influence on the risk-class. In 
addition, the high correlation coefficient of the middle category permits 
to rank the compounds according to their IC50 value between 1 and 
10 µM. This has important implications for real life project support. 
For projects with a high scatter of IC50 values, binning may be of 
sufficient help to identify promising compounds. However, if many 
compounds would fall into the middle category, simple binning would 
be of no help to guide chemical optimisation. Since the integrated two-
point method maintains the ranking power of the six-point method, it 
can fully be replaced without losing resolution for structure based 
support of medicinal chemistry and rational guidance of lead 
optimization. 
 
When comparing the one/two-point methods to the reference six-point 
method, there are at least two possible explanations for deviations 
between either two methods: (i) When analyzing six points, it is 
obviously easier to spot experimental outliers or auto-florescence of a 
compound than by looking at just one or two-points. Thus, with fewer 
inhibitor concentrations used for the calculation, we loose the 
possibility of a-posteriori correcting the experimental data based on 
visual inspection. (ii) It is easier to cope with variability when 
analyzing six data points in contrast to just one or two, since errors will 
average out in the former case. As the analysis demonstrates the 
predictive power of the proposed integrated two-point method is 90% 
suggesting that by using this approach two measurements contain 
enough information for predicting a risk class of a NCE even without 
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the possibility of excluding misleading data points from the analysis 
like in the six-point method. In pharmaceutical practise the 
performance will even be higher compared to our analysis because only 
compounds with an IC50 less than 30 µM were taken as a basis for the 
study, and NCEs showing very weak or no potential for CYP inhibition 
are determined easily. 
The integrated two-point method is directly linked to the classification 
of the inhibitory potential into the three risk-classes high (IC50≤ 
1 µM), medium (1 µM<IC50<10 µM) and low (IC50≥ 10 µM). In 
principle, the approach can easily be adapted to a different 
classification scheme. However, if the distance between the boundary 
concentrations chosen becomes too large (e.g. 2 orders of magnitude), 
the dispersion is likely to be increasing between these points, thereby 
compromising the resolution within this class. 
5  Conclusion 
In this article we show that the proposed integrated two point method 
allows reducing the number of concentrations from six to two while 
maintaining the resolution of the assay, both in terms of binning 
compounds into three risk classes and in reliably ranking compounds 
binned into the middle class. 
The predictive power of the proposed integrated two-point method is 
90% compared to the reference six-point IC50 method, which is well 
within the experimental error of the method. The method is attractive 
for automated assays which often run with few concentrations, and may 
allow to fully abandon the six point method from screening. 
In conclusion, a validated, rapid and cost effective ranking and 
prioritization tool to estimate the drug-drug interaction potential for 
NCEs at an early stage of the drug discovery process is presented 
herein. The approach can easily be adapted to different assay protocols 
or borders of risk classification.  
 
Acknowledgements 
 B.K. has been supported by the International Max-Planck Research 
School CBSC, Berlin and the Schering AG, Berlin. W.H. 
acknowledges financial support by the DFG Research Center 
MATHEON, Berlin. Jörg Seidler, Dr. Herbert Schneider and Dr. Roland 
Neuhaus are acknowledged for the supply of the experimental IC50 
values and critical discussions regarding assay principle and data. 
 
 
Published in J Biomol Screen. Online Nov 27, 2006 
References 
[1] Cohen LH, Remley MJ, Raunig D, Vaz ADN: In vitro drug 
interactions of cytochrome p450: an evaluation of fluorogenic 
to conventional substrates. Drug Metab Dispos 2003; 
31(8):1005–15. 
[2] Crespi CL, Miller VP, Penman BW: Microtiter plate assays 
for inhibition of human, drug-metabolizing cytochromes 
P450. Anal Biochem 1997; 248(1):188–90. 
[3] Deuflhard P, Hohmann A: Numerical Analysis in Modern 
Scientific Computing: An Introduction. New York: Springer, 
2003. 
[4] Gao F, Johnson DL, Ekins S, Janiszewski J, Kelly KG, Meyer 
RD, West M: Optimizing higher throughput methods to assess 
drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single 
point IC(50). J Biomol Screen 2002; 7(4):373–82. 
[5] Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ: 
Fully automated analysis of activities catalysed by the major 
human liver cytochrome P450 (CYP) enzymes: assessment of 
human CYP inhibition potential. Xenobiotica 1999; 29:53–75. 
[6] Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, 
Houston JB, Tremaine LM: The utility of in vitro cytochrome 
P450 inhibition data in the prediction of drug-drug 
interactions. J Pharmacol Exp Ther 2006; 316(1):336–48. 
[7] Ueng YF, Kuwabara T , Chun YJ, Guengerich FP: 
Cooperativity in oxidations catalyzed by cytochrome P450 
3A4. Biochemistry 1997; 36(2):370–81. 
[8] Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt 
DJ: Drug metabolism and drug interactions: application and 
clinical value of in vitro models. Curr Drug Metab 2003; 
4(5):423–59. 
[9] Wienkers LC, Heath TG: Predicting in vivo drug interactions 
from in vitro drug discovery data. Nat Rev Drug Discov 2005; 
4(10):825–33. 
[10] Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, 
Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug 
interactions for UDP-glucuronosyltransferase substrates: a 
pharmacokinetic explanation for typically observed low 
exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004; 
32(11):1201–8. 
[11] Zlokarnik G, Grootenhuis PDJ, Watson JB: High throughput 
P450 inhibition screens in early drug discovery. Drug Discov 
Today 2005; 10(21):1443–50. 
Published in J Biomol Screen. Online Nov 27, 2006 
 
CYP 1A2 2C9 2C19 2D6 3A4 
NADP+ 8.1 µM 8.1 µM 8.1 µM 8.1 µM 8.1 µM 
G6P 0.4 mM 0.4 mM 0.4 mM 0.4 mM 0.4 mM 
G6PD 0.2 IU/ml 0.2 IU/ml 0.2 IU/ml 0.2 IU/ml 0.2 IU/ml 
MgCl2 0.41 mM 0.41 mM 0.41 mM 0.41 mM 0.41 mM 
KPO4 50 mM 50 mM 50 mM 50 mM 200 mM 
Positiv controls 0.045-100µM  
Furafylline 
0.005-10µM  
Sulfaphenazole 
0.045-100 µM  
Tranyl- 
cypromine 
0.0002-0.5µM  
Quinidine 
0.00025-0.56µM 
Ketoconazole 
Enzyme amount 0.5  
pmol/well 
1  
pmol/well 
1.5  
pmol/well 
1.5  
pmol/well 
1.0  
pmol/well 
Substrate 5 µM  
CEC 
37.5 µM  
7-MFC 
25 µM  
CEC 
1.5 µM  
AMMC 
50 µM  
7-BFC 
Incub. time 15 min 45 min 30 min 30 min 30 min 
Excitation/ 
Emmission 
410/ 
460 nm 
410/ 
530 nm 
410/ 
460 nm 
390/ 
460 nm 
410/ 
530 nm 
Table I: Concentrations of used materials set up of the Crespi 
assay for different iso-enzymes. 
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Method Correctly 
predicted risk 
classes 
Number of data points in 
each class 
Pearson correlation coef.  
based on all data / for 
middle risk class 
One-point 
method at 1.1µM 
81 % 
    
0.2471/ 
0.5279 
One-point 
method at 3.3µM 
83 % 
     
0.6967/ 
0.7961 
One-point 
method at 10µM 
83 % 
     
0.8884/ 
0.8631 
Weighted one-
point method 
86 % 
     
0.5549/ 
0.7977 
Integrated two-
point method 
with Hill  
coef. =1 
90 % 
     
0.8867/ 
0.9577 
Integrated two-
point method 
with variable Hill 
coef. 
90 % 
     
0.8401/ 
0.9523 
  
Table II:  Overall evaluation of the methods for classifying compounds 
according to their inhibition potential on five CYP Isoenzymes. 
